IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Careers
    • Overview
    • Life at IMV
  • The DPX™ Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
    • Annual General and Special Shareholders Meeting
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Email Alerts
  • Annual General and Special Shareholders Meeting
Feb 25, 2020 3:05am EST

IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

Feb 20, 2020 7:05am EST

IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

Feb 14, 2020 7:05am EST

IMV Announces Board Retirement

Feb 04, 2020 7:05am EST

Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 31, 2020 7:05am EST

IMV to Present at 2020 BIO CEO & Investor Conference

Jan 24, 2020 7:05am EST

IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

Dec 08, 2019 12:05pm EST

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

Nov 27, 2019 7:05am EST

IMV to Participate at Two Upcoming Investor Conferences

Nov 08, 2019 7:05am EST

IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 06, 2019 9:01am EST

Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting

RSS
  • Prev
  • 1...
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • ...40
  • Next
IMV Inc.
About Us Careers The DPX™ Platform Clinical Pipeline News & Events Investors Contact
Twitter LinkedIn Youtube
© 2022 IMV Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap